Ticker brief

TVTX TRAVERE THERAPEUTICS INC

Consumer, Non-cyclical · Biotechnology

last close
$56.92
1 day
+1.0%
14 days
+3.2%
mkt cap
$5.3B
signals 14d
9
authors 14d
7
Sentiment — last 14 days
daily mean sentiment, 2026-06-21 → 2026-06-30 · now -0.10 (−1 bearish … +1 bullish)
Who spoke7
authorgradetrader scoresignalsmean sent
@Venu_7_B-0.452+0.30
@fundmyfundB-2.012+0.25
@akishoreC+1.671+0.35
@davevermilionA-2.031+0.15
@SandmanMarketsC-2.281+0.25
@Quantumup1C-1.951+0.55
@fj_nextstageC+1.071+0.10
Recent signals9of 9 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-06-30@fundmyfund-0.10Closed TVTX for 2.5% loss; open to re-entry if it reverses.+0.2%
2026-06-28@Venu_7_+0.35IBD Top 15 list focused on AI infrastructure, semis and healthcare.-3.3%
2026-06-26@fj_nextstage+0.10IBD50 rank-up and rank-down data with 30-week charts.-3.3%
2026-06-26@fundmyfund+0.60New position TVTX — Explicit new TVTX position on breakout with stop at 9 EMA about 3% below entry.-3.3%
2026-06-25@Quantumup1+0.55Guggenheim raised TVTX PT to $65 from $56 and reiterated Buy/Best Idea.-3.6%
2026-06-25@SandmanMarkets+0.25Reports TVTX reached 100% gains and says biotech remains hot.-3.6%
2026-06-24@davevermilion+0.15Mentions owned names and watching TEM with mild constructive view.-1.3%
2026-06-22@akishore+0.35Says ABBV's 49% premium may draw attention to mid-cap immunology players NUVL and TVTX.+3.3%
2026-06-21@Venu_7_+0.25Biotech ETF described as Stage 2 uptrend with accumulation and constructive sector setup.+3.2%

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.